Persistent depressive disorder (PDD) is the chronic, low-grade cousin of major depression — and clinicians underestimate it at their patients' expense. DSM-5-TR consolidated the older categories of dysthymic disorder and chronic major depressive disorder into a single diagnosis defined by depressed mood lasting at least two years in adults (one year in children and adolescents), with limited symptom-free intervals. Patients often describe themselves as having been depressed "as long as I can remember," and many present only after a superimposed major depressive episode — the so-called double depression — drives them to care. Functional impairment, suicide risk, and treatment resistance often equal or exceed those seen in episodic Major depressive disorder, yet PDD remains under-recognized in primary care and on consult services. The clinical bottom line: chronicity changes the treatment calculus, with combined pharmacotherapy and structured psychotherapy — particularly the Cognitive Behavioral Analysis System of Psychotherapy (CBASP) — outperforming either modality alone for most patients.

PDD is less prevalent than episodic major depression but disproportionately contributes to depression-related disability because of its chronic course. Recognition rates in primary care are low; many patients carry the burden for a decade or more before a formal diagnosis is made.^1-2

Prevalence and onset

• 12-month prevalence in U.S. adults is approximately 0.5%, with lifetime prevalence near 2.5-3% when chronic depressive disorders are aggregated.^1,3
• Mean age of onset is in the early 20s, with a substantial early-onset subgroup beginning before age 21 that carries higher comorbidity and treatment resistance.^2-3
• Female-to-male ratio is approximately 2:1, mirroring major depressive disorder.¹
• Prevalence is elevated in primary care populations (3-6%) compared with community samples.²

Comorbidity

• More than 75% of patients with PDD meet criteria for at least one additional psychiatric disorder over the lifetime.^2,4
• Anxiety disorders, particularly generalized anxiety disorder and social anxiety disorder, co-occur in roughly half of cases.²
• Substance use disorders are present in 20-30%, with alcohol use disorder predominating.^2,4
• Personality disorders — especially Cluster C (avoidant, dependent, obsessive-compulsive) — co-occur frequently and complicate treatment.^2,4
• Lifetime suicide attempt rates approach those of major depressive disorder and exceed community baselines several-fold.⁴

Risk factors

• Family history of mood disorder, particularly first-degree relatives with chronic depression or bipolar disorder.^2,5
• Childhood adversity, including early loss, neglect, and physical or sexual abuse, is among the most robust environmental predictors.^5-6
• Female sex, low socioeconomic status, and chronic medical illness (especially cardiovascular disease, diabetes, and chronic pain).^1-2
• Early age of first depressive episode predicts chronicity.⁵

No single mechanism explains PDD, and most pathophysiologic findings overlap with major depressive disorder. What distinguishes the chronic phenotype appears to be the early developmental loading of risk — childhood adversity, early temperamental traits, and persistent stress-system dysregulation rather than a discrete neurochemical lesion.^5-6

Neurobiology

• Monoaminergic dysregulation — serotonin, norepinephrine, and dopamine — underlies most current pharmacologic models, though the simple "depletion" framework has been superseded by network and plasticity models.⁷
• Hypothalamic-pituitary-adrenal axis dysregulation is observed in chronic depression, with blunted cortisol awakening responses and altered dexamethasone suppression in some patients.^5-6
• Reduced hippocampal volume and altered prefrontal-limbic connectivity, including default mode network hyperconnectivity, are reported in chronic depression cohorts.^6-7
• Inflammatory markers (CRP, IL-6, TNF-alpha) are modestly elevated in subgroups, supporting a neuroinflammation-plasticity model.⁷

Genetics

• Heritability estimates for chronic depression range from 30-40%, similar to major depressive disorder.⁵
• No single high-impact gene has been replicated; polygenic risk scores derived from major depression GWAS partially predict chronic depressive phenotypes.^5,7
• Gene-environment interactions, particularly involving early-life adversity and stress-response gene variants, are under active study.⁶

Environmental and psychosocial factors

• Chronic interpersonal stress, ongoing role strain, and unresolved early trauma maintain the depressive state and shape the cognitive-interpersonal patterns CBASP targets.⁸
• McCullough's developmental model frames PDD as arrested socioemotional development with pre-operational thinking — patients fail to recognize that their behavior produces predictable consequences in others.⁸

DSM-5-TR collapsed dysthymic disorder and chronic major depressive disorder into persistent depressive disorder, recognizing that the older categorical split was artificial and that chronicity itself is the clinically meaningful axis.⁹ The two-year duration requirement (one year in youth) remains the diagnostic spine.⁹

DSM-5-TR criteria for persistent depressive disorder

• Depressed mood for most of the day, more days than not, for at least two years in adults or one year in children and adolescents.⁹
• At least two of the following while depressed: poor appetite or overeating, insomnia or hypersomnia, low energy or fatigue, low self-esteem, poor concentration or difficulty making decisions, and feelings of hopelessness.⁹
• During the two-year period (one year in youth), the patient has not been without the symptoms above for more than two months at a time.⁹
• Criteria for a major depressive episode may be continuously present for two years.⁹
• No history of mania or hypomania, and criteria for cyclothymic disorder have never been met.⁹
• The disturbance is not better explained by a persistent psychotic disorder.⁹
• Symptoms are not attributable to a substance or another medical condition.⁹
• Clinically significant distress or impairment in functioning is present.⁹

Specifiers

• With anxious distress, with mixed features, with melancholic features, with atypical features, with mood-congruent or mood-incongruent psychotic features, and with peripartum onset.⁹
• Course specifiers: in partial remission, in full remission, early onset (before age 21), late onset (age 21 or older).⁹
• Subtype specifiers reflecting the prior diagnostic split: with pure dysthymic syndrome, with persistent major depressive episode, with intermittent major depressive episodes (with or without current episode).⁹
• Severity: mild, moderate, or severe.⁹

ICD-11 differences

• ICD-11 retains a separate code for dysthymic disorder (6A72) within the depressive disorders chapter rather than merging it with chronic major depression.¹⁰
• ICD-11 does not require a fixed minimum symptom count; a persistent depressive presentation lasting at least two years with most days affected suffices.¹⁰
• The DSM-5-TR concept of "persistent depressive disorder with persistent major depressive episode" maps approximately to ICD-11 "recurrent depressive disorder, current episode, with persistent course."¹⁰

The clinical signature of PDD is a flat, sustained depressive baseline rather than discrete episodes, often with cognitive and interpersonal features that look more like personality pathology than mood pathology on first contact. Patients are frequently described — by themselves and by others — as gloomy, pessimistic, or low-functioning by temperament.^2,8

Symptom profile

• Cognitive features predominate: Anhedonia, hopelessness, low self-esteem, indecisiveness, and rumination.^2,9
• Neurovegetative symptoms (sleep, appetite, energy) are present but often less prominent than in acute major depressive episodes.²
• Suicidal ideation tends to be passive and chronic rather than acute and crisis-driven, but lifetime attempt rates remain high.⁴
• Functional impairment compounds over time — occupational underachievement, social withdrawal, and relationship instability are common by mid-adulthood.^2,11

Course patterns

• Pure dysthymic syndrome: chronic low-grade symptoms without ever meeting full major depressive episode criteria.⁹
• Double depression: a superimposed major depressive episode on baseline dysthymia, the most common reason patients with PDD seek care.^2,11
• Persistent major depressive episode: full MDD criteria met continuously for at least two years.⁹
• Intermittent major depressive episodes with persistent dysthymic baseline between episodes.⁹

Atypical and red-flag presentations

• Atypical features (mood reactivity, leaden paralysis, hypersomnia, hyperphagia, rejection sensitivity) are over-represented in early-onset PDD.^2,12
• Sudden mood elevation or irritability raises concern for an emerging hypomanic episode and reclassification to bipolar II disorder.⁹
• Acute worsening of suicidal ideation, psychotic features, or catatonic signs warrants reassessment for a superimposed major depressive episode with psychotic or melancholic features.^2,9

The differential for chronic low mood is broad, and the most common error is anchoring on PDD without ruling out a treatable medical contributor or a missed bipolar diathesis.^2,11

Psychiatric differentials

• Major depressive disorder, recurrent: episodes are discrete with clear euthymic intervals exceeding two months; PDD by definition lacks this symptom-free window.⁹
• Bipolar II disorder: a careful history for hypomanic episodes is mandatory; missed hypomania is a leading cause of misdiagnosis in chronic depression.^9,11
• Cyclothymic disorder: alternating subthreshold depressive and hypomanic symptoms over at least two years, without ever meeting major depressive or hypomanic episode criteria — diagnosis of PDD is exclusionary if cyclothymia has been met.⁹
• Adjustment disorder with depressed mood: identifiable stressor, onset within three months, and resolution within six months of stressor termination.⁹
• Generalized anxiety disorder: chronic worry and somatic anxiety can mimic dysthymic dysphoria; the two frequently co-occur.²
• Personality disorders, especially Cluster C and borderline personality disorder: pervasive depressive cognitions and interpersonal dysfunction can mimic PDD, and the disorders frequently co-occur.^2,4
• Substance/medication-induced depressive disorder: alcohol, benzodiazepines, opioids, interferon, corticosteroids, and certain antihypertensives.^2,9
• Premenstrual dysphoric disorder: cyclical pattern with luteal-phase clustering, distinct from chronic baseline.⁹

Medical mimics

• Hypothyroidism — classic mimic; check TSH on every chronic depression workup.^2,11
• Anemia, vitamin B12 deficiency, vitamin D deficiency, and iron deficiency.²
• Obstructive sleep apnea, particularly when fatigue and concentration complaints dominate.¹¹
• Neurologic disease: Parkinson disease, multiple sclerosis, post-stroke depression, and early dementia, especially when onset is late-life.^2,11
• Autoimmune and inflammatory conditions: SLE, rheumatoid arthritis, and inflammatory bowel disease.²
• Endocrine: Cushing syndrome, hyperparathyroidism, hypogonadism.²
• Occult malignancy, particularly pancreatic cancer with depressive prodrome.²

Assessment combines a longitudinal history — the only way to establish chronicity — with targeted screening for mimics and comorbidities. A snapshot mental status exam alone cannot diagnose PDD; the diagnosis is built across encounters or with collateral.^2,11

History essentials

• Detailed timeline of mood across years, anchored to school, work, and relationship milestones to establish the two-year minimum.²
• Explicit screen for past hypomania (decreased sleep need with sustained energy, goal-directed activity, observable behavioral change).^9,11
• Substance use history including alcohol, cannabis, prescription opioids, benzodiazepines, and stimulants.²
• Trauma and adversity history (ACE exposure, intimate partner violence, ongoing role strain).^5-6
• Family psychiatric history with attention to chronicity, suicide, and bipolar disorder in first-degree relatives.⁵
• Suicide risk assessment with attention to chronic passive ideation and access to lethal means.⁴

Physical exam and labs

• Vital signs, BMI, thyroid exam, and a focused neurologic exam.²
• Baseline labs for any new chronic depression: TSH, CBC, comprehensive metabolic panel, vitamin B12, vitamin D, and pregnancy test where applicable.^2,11
• HbA1c and lipid panel for cardiometabolic baseline before initiating antidepressants with metabolic effects.¹¹
• ECG before starting QTc-prolonging agents (citalopram >40 mg, tricyclic antidepressants) in older patients or those with cardiac risk.¹³
• Imaging is not routine; reserve MRI brain for atypical features, focal neurologic findings, or late-life new-onset presentation.¹¹

Validated rating scales

• PHQ-9 — primary care-friendly, scores 0-27, monitors response over time.¹⁴
• Hamilton Depression Rating Scale (HAM-D) — clinician-administered, gold standard in research.¹⁵
• Montgomery-Asberg Depression Rating Scale (MADRS) — clinician-administered, more sensitive to change than HAM-D in chronic depression trials.¹⁶
• Inventory of Depressive Symptomatology, Self-Report (IDS-SR) and the Quick Inventory (QIDS-SR) — used in STAR*D and well-suited to chronic course tracking.¹⁷
• Cornell Dysthymia Rating Scale — purpose-built for chronic low-grade depression, though less widely used.¹⁸
• Mood Disorder Questionnaire (MDQ) — screen for past hypomania before committing to a unipolar diagnosis.¹⁹

Treatment of PDD differs from acute MDD in two ways that matter at the bedside: response is slower, and combination therapy outperforms monotherapy more reliably than in acute episodes. Patients have often failed prior antidepressant trials, and engagement is itself a therapeutic target.^20-21

Pharmacotherapy

• SSRIs are first-line; sertraline, fluoxetine, escitalopram, and paroxetine all have evidence in chronic depression and dysthymia.^20,22
• SNRIs (venlafaxine, duloxetine) are reasonable alternatives, particularly when comorbid anxiety or chronic pain is present.^20,22
• Tricyclic antidepressants (imipramine in particular) have the longest evidence base in dysthymia trials but are second-line because of tolerability and overdose risk.^20-21
• Bupropion is an option when sexual dysfunction or fatigue dominates, though evidence specifically in chronic depression is more limited.²⁰
• Adequate trial duration is at least 8-12 weeks at therapeutic dose; chronic depression responds more slowly than acute MDD.^20-21
• Maintenance pharmacotherapy is recommended after remission given high relapse rates; many guidelines recommend continuation for at least two years and often indefinitely.^20-21

Psychotherapy

• Cognitive Behavioral Analysis System of Psychotherapy (CBASP) is the only psychotherapy developed specifically for chronic depression and has the strongest evidence in this population.^8,21,23
• Cognitive behavioral therapy (CBT) and interpersonal psychotherapy (IPT) have evidence in chronic depression, though effect sizes in pure dysthymia are modest as monotherapy.^20-21
• Behavioral activation is effective and pragmatic, particularly in primary care settings.²⁰
• Mindfulness-based cognitive therapy (MBCT) reduces relapse risk in residual depression, with growing evidence in chronic phenotypes.²⁴
• Schema therapy and short-term psychodynamic psychotherapy have moderate evidence and are reasonable when personality features dominate.²¹

Combined treatment

• The Keller et al. trial (Keller MB, et al., NEJM 2000) demonstrated that nefazodone plus CBASP produced a 73% response rate versus 48% for either monotherapy in chronic depression — a landmark result establishing combined treatment as the standard.²³
• Subsequent trials and meta-analyses confirm that combined pharmacotherapy and psychotherapy outperform either alone for chronic depression, particularly when childhood trauma is present.^21,25
• Strong evidence supports combination as the preferred initial strategy in early-onset and trauma-exposed PDD.^21,25

Treatment-resistant approaches

• Switch within class (one SSRI to another) or across class (SSRI to SNRI, or to bupropion) after an adequate failed trial.²⁶
• Augmentation strategies include lithium, low-dose atypical antipsychotics (aripiprazole, quetiapine extended-release, brexpiprazole), thyroid hormone (T3), and bupropion add-on, drawing on STAR*D and adjunctive antipsychotic data.^26-27
• MAOIs (phenelzine, tranylcypromine) retain a role in atypical and treatment-resistant chronic depression with appropriate dietary precautions.^20,26
• Esketamine intranasal is FDA-approved for treatment-resistant depression and may be considered for PDD with persistent major depressive episode meeting TRD criteria.²⁸

Neuromodulation

• Repetitive transcranial magnetic stimulation (rTMS) is FDA-approved for treatment-resistant major depressive disorder and is commonly applied in chronic depression that has failed pharmacotherapy.²⁹
• Electroconvulsive therapy (ECT) remains the most effective treatment for severe depression and is appropriate for PDD with persistent major depressive episode that is severe, psychotic, catatonic, or acutely suicidal.³⁰
• Vagus nerve stimulation has FDA approval for treatment-resistant depression but is rarely used as first-line neuromodulation.³¹

Adjunctive

• Aerobic exercise (3-5 sessions/week of moderate-intensity activity) is recommended as adjunctive treatment with evidence for moderate antidepressant effect.³²
• Sleep hygiene and treatment of comorbid insomnia or obstructive sleep apnea, both of which can perpetuate depressive symptoms.¹¹
• Treatment of comorbid substance use disorders, given that ongoing alcohol or stimulant use undermines antidepressant response.^2,4
• Bright light therapy has evidence in seasonal and non-seasonal depression and is a low-risk adjunct.³³

The harms picture in PDD is dominated by long treatment exposure rather than acute adverse events. Patients are on antidepressants for years, often decades, and cumulative effects matter.^20-21

Common adverse effects

• SSRI/SNRI: GI upset, sexual dysfunction (often persistent), weight changes, sleep disruption, and emotional blunting.^20,22
• Tricyclic antidepressants: anticholinergic effects, orthostasis, weight gain, and cardiac conduction changes.²⁰
• Atypical antipsychotic augmentation: weight gain, metabolic syndrome, akathisia, and prolactin elevation.²⁷

Serious or rare adverse effects

• Serotonin syndrome with combined serotonergic agents (SSRIs, SNRIs, MAOIs, tramadol, linezolid, triptans).²⁰
• SIADH and hyponatremia, particularly in older adults on SSRIs.²⁰
• QTc prolongation with citalopram >40 mg/day and tricyclic antidepressants.¹³
• Increased bleeding risk with SSRIs, particularly when combined with NSAIDs or anticoagulants.²⁰
• Tardive dyskinesia with prolonged atypical antipsychotic exposure.²⁷

Monitoring and discontinuation

• Antidepressant discontinuation syndrome — flu-like symptoms, paresthesias ("brain zaps"), insomnia, and mood instability — is common with abrupt cessation, particularly of paroxetine and venlafaxine.³⁵
• Slow taper over weeks to months is recommended after long-term use.³⁵
• Periodic reassessment of indication, dose, and need for ongoing pharmacotherapy is appropriate even when remission is sustained.²⁰
• Lifetime monitoring for emergent hypomania given the substantial rate of bipolar reclassification in chronic depression cohorts.¹¹

Limitations of the evidence base

• Many landmark trials (including Keller 2000) used nefazodone, which is now rarely prescribed because of hepatotoxicity, complicating direct translation to current pharmacotherapy.²³
• Trial follow-up is often shorter than the natural course of PDD, limiting inference about long-term durability.²¹
• Patients with severe comorbidity, substance use, or active suicidality are systematically excluded from RCTs, narrowing generalizability.²¹
• Comparative effectiveness data between specific SSRIs and SNRIs in PDD are limited; most extrapolation is from MDD trials.²⁰

The diagnosis carries different implications across the lifespan and across comorbid medical contexts. Tailoring is the rule, not the exception.^2,11

Children and adolescents

• Duration requirement is reduced to one year, and irritable mood may substitute for depressed mood.⁹
• Early-onset PDD (before age 21) is associated with higher comorbidity, more severe course, and stronger family loading.^2,5
• Fluoxetine and escitalopram have FDA approval for pediatric depression; sertraline has approval for pediatric OCD and is commonly used off-label for depression.³⁴
• TADS and TORDIA trials support combined fluoxetine plus CBT in adolescent depression, with response rates higher than monotherapy.^36-37
• Black box warning for suicidality applies; close monitoring at initiation and dose change is mandatory.³⁴

Older adults

• Late-onset PDD warrants more aggressive medical workup, including neurologic evaluation for vascular depression and early dementia.¹¹
• SSRIs (sertraline, escitalopram) are preferred; avoid paroxetine because of anticholinergic burden.^11,38
• Citalopram is restricted to 20 mg/day maximum in adults over 60 due to QTc concerns.¹³
• Tricyclic antidepressants are generally avoided due to falls, anticholinergic effects, and cardiac risk.³⁸
• Hyponatremia risk with SSRIs is elevated; check sodium 2-4 weeks after initiation in higher-risk patients.³⁸

Perinatal

• Sertraline is among the preferred SSRIs in pregnancy and lactation given low placental transfer and minimal breast milk concentration.³⁹
• Paroxetine is associated with a small increased risk of cardiac malformations and is generally avoided in pregnancy.³⁹
• Untreated chronic depression in pregnancy carries its own risks, including preterm birth, low birth weight, and postpartum depression.³⁹
• Risk-benefit discussion and shared decision-making are essential.³⁹

Comorbid medical illness

• Cardiovascular disease: sertraline has the most safety data post-MI; tricyclic antidepressants are avoided.⁴⁰
• Chronic pain: SNRIs (duloxetine, venlafaxine) and tricyclic antidepressants offer dual analgesic and antidepressant effects.²⁰
• Hepatic impairment: dose reduction is required for most antidepressants; sertraline and citalopram are reasonable choices with caution.²⁰

Comorbid substance use

• Active alcohol use disorder undermines antidepressant response; concurrent treatment of both disorders is recommended rather than sequential.^2,4
• Naltrexone, acamprosate, and disulfiram for alcohol use disorder may be combined with antidepressants without major pharmacokinetic concerns.²

Cultural considerations

• Somatic presentations of depression (fatigue, pain, GI complaints) predominate in many non-Western cultural contexts and may delay recognition of PDD.^2,11
• Stigma, family structure, and explanatory models for chronic illness shape engagement and adherence.¹¹

PDD is a chronic illness. Spontaneous remission is uncommon, and even with treatment many patients experience residual symptoms or recurrence over decades.^2,11,21

Natural history

• Without treatment, only 10-15% of patients with dysthymia achieve sustained remission within five years.²
• With treatment, response rates are 45-55% and full remission rates 25-35% at one year, lower than acute MDD.^20-21
• Approximately 75% of patients with pure dysthymia eventually develop a superimposed major depressive episode (double depression).^2,11
• Functional recovery lags symptomatic recovery; many patients with sustained remission continue to report occupational and interpersonal impairment.¹¹

Suicide and mortality

• Lifetime suicide attempt rates in PDD approach those in MDD and substantially exceed community baselines.⁴
• All-cause mortality is elevated in chronic depression, mediated by cardiovascular disease, suicide, and accidents.^4,11
• Persistent suicidal ideation is more common than acute suicidal crisis in PDD, but should not be dismissed as "chronic" or "baseline."⁴

Predictors of poor outcome

• Early age of onset, longer duration before treatment, and greater symptom severity at baseline.^2,11
• Childhood trauma history, comorbid personality disorder, and ongoing chronic stress.^5-6
• Comorbid anxiety, substance use, or chronic medical illness.^2,4
• Treatment non-adherence and inadequate trial duration of prior antidepressants.^20-21

Although PDD is a chronic, low-grade illness, decompensation into acute crisis is common — particularly when a major depressive episode is superimposed or when a missed bipolar diathesis emerges. Standing chronic risk does not equal absent acute risk.^4,11

Hospitalization criteria

• Acute suicidal ideation with intent, plan, or recent attempt.⁴
• Inability to maintain basic self-care, severe weight loss, or catatonia.²
• Psychotic features, especially command hallucinations or nihilistic delusions.²
• Acute substance intoxication or withdrawal complicating the depressive presentation.²
• Lack of outpatient containment (no support, no provider continuity) in a high-risk patient.⁴

Suicide risk markers

• Prior attempt is the single strongest predictor of future attempt and completed suicide.⁴
• Hopelessness predicts suicide independently of depressive symptom severity.⁴
• Access to lethal means, particularly firearms, dramatically elevates short-term risk; means restriction is a core intervention.⁴
• Recent psychiatric hospitalization, recent major loss, and acute alcohol use are short-term escalators.⁴

Agitation and acute presentations

• Agitated depression with mixed features warrants reassessment for bipolar spectrum and may respond to mood stabilizers or atypical antipsychotics rather than antidepressant uptitration.^9,11
• Sudden onset of insomnia, racing thoughts, or irritability after antidepressant initiation raises concern for treatment-emergent hypomania.¹¹
• Severe melancholic or psychotic features with persistent major depressive episode warrant ECT consideration.³⁰

The merger of dysthymia and chronic MDD into PDD remains debated, and important questions about treatment specificity and long-term management are unresolved.^9,21

Diagnostic boundaries

• Critics argue that collapsing dysthymia and chronic MDD into PDD obscures clinically meaningful differences in symptom severity and treatment response.²¹
• ICD-11 retained the separate dysthymia category, reflecting ongoing disagreement.¹⁰
• The boundary between PDD and depressive personality features remains conceptually fuzzy, with implications for whether to prioritize pharmacologic versus psychological intervention.^8,21

Treatment specificity

• Whether CBASP retains its advantage over generic CBT in heterogeneous chronic depression cohorts is contested; some recent trials show smaller effects than the original Keller study.^21,25
• The role of childhood trauma as a moderator of treatment response is increasingly recognized but not yet standard in treatment-matching algorithms.^6,25

Long-term pharmacotherapy

• Optimal duration of maintenance pharmacotherapy after sustained remission is uncertain; recommendations range from two years to indefinite.^20-21
• Concerns about long-term SSRI exposure (sexual dysfunction, emotional blunting, post-SSRI sexual dysfunction) are underrepresented in trial data and increasingly raised in patient communities.³⁵

Emerging treatments

• Esketamine and ketamine for treatment-resistant depression have rapid antidepressant effects but limited data specifically in PDD; durability beyond a few months is uncertain.²⁸
• Psilocybin-assisted therapy is in late-phase trials for treatment-resistant depression and may eventually be evaluated in chronic depression phenotypes; regulatory status remains experimental.[CITE NEEDED]
• Digital and remote-delivered CBT and behavioral activation programs show promise for scalability but evidence specifically in chronic depression is limited.²⁴

• DSM-5-TR persistent depressive disorder requires depressed mood most of the day, more days than not, for at least two years in adults (one year in youth, where irritability may substitute).⁹
• At least two of the six dysthymia symptoms (poor appetite/overeating, insomnia/hypersomnia, low energy, low self-esteem, poor concentration/decision-making, hopelessness) must be present.⁹
• Symptom-free intervals during the diagnostic period cannot exceed two consecutive months.⁹
• DSM-5-TR consolidated dysthymic disorder and chronic major depressive disorder into PDD; ICD-11 kept dysthymia separate.^9-10
• Double depression refers to a major depressive episode superimposed on baseline dysthymia and is the most common reason patients with PDD seek care.^2,11
• A history of mania or hypomania excludes PDD; cyclothymic disorder is also exclusionary.⁹
• Mean age of onset is in the early 20s; early onset (before 21) carries higher comorbidity and treatment resistance.^2-3
• The Keller 2000 NEJM trial demonstrated superiority of combined nefazodone plus CBASP over either monotherapy in chronic depression.²³
• CBASP is the only psychotherapy specifically developed for chronic depression.^8,23
• Adequate antidepressant trial duration in chronic depression is at least 8-12 weeks at therapeutic dose.^20-21
• Citalopram is restricted to 20 mg/day maximum in adults over 60 due to QTc prolongation.¹³
• Sertraline is preferred among SSRIs in pregnancy and lactation; paroxetine is generally avoided due to cardiac malformation risk.³⁹
• All antidepressants carry an FDA black box warning for increased suicidal ideation in patients under 25.³⁴
• Hypothyroidism is the classic medical mimic; TSH belongs on every chronic depression workup.^2,11
• Hopelessness predicts suicide independently of depressive symptom severity.⁴

No external funding. No conflicts of interest declared. Peer-review status: pending.